regulation is the sole category represented across all 1 tracked stories. Patrick Soon-Shiong is most often covered alongside FDA, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Patrick Soon-Shiong
regulation is the sole category represented across all 1 tracked stories. Patrick Soon-Shiong is most often covered alongside FDA, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 6.3. We currently track 1 Legal story that mention Patrick Soon-Shiong, all published on March 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 56 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Patrick Soon-Shiong. Shared-story counts are live from our verified record — not editorial picks.
The FDA has issued a formal warning to billionaire Patrick Soon-Shiong regarding misleading promotional statements about ImmunityBio’s bladder cancer treatment. The regulatory action highlights a growing crackdown on off-label marketing conducted through non-traditional media channels like podcasts.